Company news

Rhythm Biosciences Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Genetype Commercial Integration Completion

February 3, 2025

Quarterly Activities Report and Appendix 4C - Dec24

January 22, 2025

About the Genetype Acquisition

January 13, 2025

Completion of Genetype Risk Assessment Portfolio Acquisition

December 23, 2024

RHY Acquires Genetype Genetic Risk Assessment Business

December 22, 2024

Pause in Trading

December 20, 2024

Market Update - All End of CY24 Milestones Attained

December 17, 2024

Strong Demand in Share Placement to Raise $3.5 million

November 18, 2024

Receipt of Research & Development Tax Incentive

November 6, 2024

2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms

October 6, 2024

Board Renewal / Composition Update

September 29, 2024

Platform Expansion - Gastric Cancer Diagnostic Test Update

September 23, 2024

Product and Market Update - Phase 2 Milestone

August 27, 2024

Jun 24 Quarterly Activities Report and Appendix 4C

July 28, 2024

Mar24 Quarterly Activities Report and Appendix 4C

April 29, 2024

Dr David Atkins appointed Chief Executive Officer of Rhythm

April 24, 2024

Rhythm Maintains ISO Certification

April 22, 2024

Close of Rights Issue

March 20, 2024

Internationally Renowned Clinical Advisory Board Established

March 18, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

Half Yearly Report and Accounts

February 28, 2024

Prospectus - 2024 Non-Renounceable Rights Issue

February 18, 2024

Rights Issue Offer to Raise Up To $6.6 million

February 8, 2024

Quarterly Activities Report and Appendix 4C - Dec23

January 30, 2024

Strategy & Market Update

December 17, 2023

Platform Expansion - Lung Cancer Diagnostic Test Update

November 23, 2023

Executive Management Changes

November 15, 2023

Receipt of First Tranche of $1.69m in R&D Tax Incentive

November 13, 2023

Response to ASX Query

October 18, 2023

RHY 2023 AGM Presentation

October 9, 2023

Investor Presentation

June 19, 2023

UK Strategic Partnership with LINK Medical Solutions

May 24, 2023

UK CA Mark granted for ColoSTAT

May 16, 2023

Executive Management Change

April 19, 2023

ColoSTAT abstracts accepted at 2023 ASCO Annual Meeting

April 6, 2023

Reinstatement to Official Quotation

March 5, 2023

Update to TGA Submission

March 5, 2023

Suspension from Official Quotation

March 3, 2023

Appendix 4D & Interim Financial Report

February 23, 2023

RHY Institutional Presentation

February 23, 2023

Appendix 4C - Quarterly

January 31, 2023

Institutional Presentation

January 24, 2023

Market Update

December 14, 2022

RHY Continues Platform Expansion Program for Other Cancers

December 14, 2022

MST Access Diagnostics Forum Presentation (Amended)

December 6, 2022

MST Access Financial Diagnostics Presentation

December 5, 2022

RHY 2022 AGM Presentation

November 29, 2022

Healthcare Conference Investor Presentation

November 8, 2022

ColoSTAT Authorised For Sale In New Zealand

November 2, 2022

Rhythm Receives $2.7m R&D Tax Incentive

October 20, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 46 decks. Every deck is listed under its year.